Validation Of Novel Nutrient Formulation For Appetite Regulation

用于食欲调节的新型营养配方的验证

• 批准号: 10028205
• 金额: $ 27.31万
• 依托单位: ENTERIKA LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10028205
• 关键词: Validation; Novel; Nutrient; Formulation; Appetite

Our scientific group has pioneered research on how our gut senses the contents of a meal since 1984\. This research has culminated in a major paper published this year showing our discovery of a novel and effective means to reduce appetite in obese people. Our company, Enterika, was set up to take this discovery to the market as a product that could then be made available for a very large unmet need -- appetite suppression and weight loss.For a while, it has been known that specialised cells in various parts of the intestine can sense different nutrients by specialised receptors (molecules) on the outsides of the cells lining the intestine wall. Our discovery was that targeting certain nutrients specifically to the lower gut (colon) gives rise to appetite suppression by activation of some of these specific sensor molecules. In turn, these cells then release hormones into the blood stream and activate sensory nerves leading to appetite suppression. A critical part of our discovery was that different nutrients act via different molecules, and only by combining the actions of more than one nutrient could we stimulate this process. Another critical finding was that naturally occurring dietary nutrients are effective in triggering this response in small quantities. This means our approach is drug-free, safe and could have broader health benefits.Our product currently consists of capsules filled with pure nutrient coated with a protective layer that only breaks down when it reaches the colon. However, many capsules are required before each meal. We aim to refine this formulation (based on recent advances in pharmacology) so it is smaller but still as effective. This will take more lab work to ensure the pathway of hormone release is adequately activated, and a clinical study in obese subjects to check that the capsules achieve their aim of inducing hormone changes and suppressing appetite. Further streamlining and optimisation will continue until we have the best product.To our knowledge, no other company or institution is pursuing the approach we have chosen. We are therefore in an ideal position to take these two clear steps towards occupying a substantial and successful part of the anti-obesity treatments market.

自1984年以来，我们的科学小组就率先研究了我们的肠道如何感知食物的内容。这项研究在今年发表的一篇重要论文中达到了高潮，该论文展示了我们发现了一种新颖有效的方法来减少肥胖人群的食欲。我们的公司，Enterika，就是为了将这一发现推向市场，作为一种产品，然后可以提供给一个非常大的未满足的需求-抑制食欲和减肥。一段时间以来，人们已经知道，肠道各个部分的专门细胞可以通过肠壁细胞外部的专门受体（分子）来感受不同的营养物质。我们的发现是，将某些营养素特异性地靶向下肠道（结肠），通过激活这些特定的传感器分子中的一些来抑制食欲。反过来，这些细胞然后释放激素到血液中，激活感觉神经，导致食欲抑制。我们发现的一个关键部分是，不同的营养素通过不同的分子起作用，只有通过组合多种营养素的作用，我们才能刺激这一过程。另一个关键发现是，天然存在的膳食营养素在少量时可有效触发这种反应。这意味着我们的方法是无毒的，安全的，可以有更广泛的健康益处。我们的产品目前包括胶囊填充纯营养涂层与保护层，只有当它到达结肠分解。然而，每餐前需要服用许多胶囊。我们的目标是改进这种配方（基于药理学的最新进展），使其更小，但仍然有效。这将需要更多的实验室工作，以确保激素释放的途径被充分激活，并在肥胖受试者中进行临床研究，以检查胶囊是否达到诱导激素变化和抑制食欲的目的。进一步的精简和优化将继续下去，直到我们有最好的产品。据我们所知，没有其他公司或机构正在追求我们所选择的方法。因此，我们正处于一个理想的位置，采取这两个明确的步骤，以占领减肥治疗市场的重要和成功的一部分。